{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-001681","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.637068+00:00","generated_at":"2026-05-26T02:17:08.770068+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Scholar Rock reports FY 2024 net loss of $2.47/share; BLA submitted for apitegromab in SMA","bullets":["Net loss $246.3M ( $2.47 /share) vs $165.8M ( $1.99 /share) in FY 2023; zero revenue.","Cash, equivalents & marketable securities $437.3M; expanded credit facility adds up to $150M in tranches.","BLA for apitegromab in SMA submitted Jan 2025; US launch planned 4Q 2025; EU MAA expected 1Q 2025.","Phase 2 EMBRAZE topline data (apitegromab+tirzepatide in obesity) expected 2Q 2025; IND for SRK-439 in 3Q 2025.","COO/CFO Ted Myles departing; search for new CFO; Lisa Wyman appointed CTQO."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-001681","json":"https://secwatch.observer/filing/0001558370-25-001681.json","markdown":"https://secwatch.observer/filing/0001558370-25-001681.md","text":"https://secwatch.observer/filing/0001558370-25-001681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/0001558370-25-001681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/srrk-20250227x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:17:08.770068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}